Treatment of novel or re-emerging pandemic influenza virus infections (limited to cases in which other influenza antiviral drugs are ineffective or not sufficiently effective).
Dosage & Administration
The usual adult dosage is 1600 mg of Favipiravir administered orally twice daily on Day 1, followed by 600 mg orally twice daily from Day 2 to Day 5. The total treatment duration should be 5 days. The administration should be started promptly after the onset of influenza-like symptoms.
Favipiravir is a drug the use of which is considered only when there is an outbreak of novel or re-emerging influenza virus infections in which other anti-influenza virus agents are not effective or insufficiently effective, and the government decides to use the drug as a countermeasure against such influenza viruses. When administering the drug, obtain the latest information including government’s direction of countermeasures against such influenza viruses, and prescribe only to appropriate patients.
Favipiravir is not effective against bacterial infections.
Favipiravir has not been administered to children.
Use in Pregnancy & Lactation
Do not administer Favipiravir to women known or suspected to be pregnant. (Early embryonic deaths [rats] and teratogenicity [monkeys, mice, rats and rabbits] have been observed in animal studies with exposure levels similar to or lower than the clinical exposure.)
When administering Favipiravir to lactating women, instruct to stop lactating. (The major metabolite of Favipiravir, a hydroxylated form, was found to be distributed in breast milk.)